HWAM
LXEO icon

Hennion & Walsh Asset Management’s Lexeo Therapeutics LXEO Stock Holding History

Hennion & Walsh Asset Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.29M Buy
381,989
+116,292
+44% +$526K 0.04% 506
2026
Q2 		$1.24M Buy
+265,697
New +$1.44M 0.04% 510

Other funds holding LXEO

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Hennion & Walsh Asset Management's LXEO Position: Q3 2026 in Review

Hennion & Walsh Asset Management increased its Lexeo Therapeutics (LXEO) stake by 44% in Q3 2026, buying an estimated $526K and bringing the position to 381,989 shares worth $1.29M. The position accounts for 0.04% of the portfolio, ranked #506.

Hennion & Walsh Asset Management first reported a position in LXEO in Q2 2026 and has held it in 2 quarters since. 4 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

  • Hennion & Walsh Asset Management held 381,989 shares of Lexeo Therapeutics worth $1.29M as of Q3 2026.
  • Hennion & Walsh Asset Management bought 116,292 Lexeo Therapeutics shares in Q3 2026, an estimated $526K.
  • Lexeo Therapeutics made up 0.04% of Hennion & Walsh Asset Management's portfolio in Q3 2026, its #506 holding.
  • Hennion & Walsh Asset Management first reported a position in Lexeo Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 4 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q3 2026, filed 13 Oct 2026.